

# European Heart Journal

## Volume 46 No. 27 July 2025

### ISSUE @ A GLANCE



**Hot topics in prevention: resistant hypertension, blood pressure variability, triglycerides, and apoB-containing lipoproteins**

*F. Crea*

2607

### CardioPulse

**Integrating non-communicable diseases awareness campaign into periodic human immunodeficiency virus awareness campaign: lessons from events of World AIDS Day in Akwa Ibom State, Nigeria**

*D. Henry, A. Ekanem, and D. Ojji; MAPIT Study Team*

2611

**The Polish way to handle the transition from children to adult congenital heart disease**

*L. Tomkiewicz-Pajak, P. Skorek, and J. Kusa*

2614

**Advances in cardiovascular medicine in Taiwan: artificial intelligence has come to the real world**

*C.-S. Lin, Y.-J. Lin, and Y.-H. Li*

2616

## FOCUS ISSUE ON HYPERTENSION AND DYSLIPIDAEMIAS

### STATE OF THE ART REVIEW



**Aldosterone-targeted therapies: early implementation in resistant hypertension and chronic kidney disease**

*M. Kobayashi, B. Pitt, J.P. Ferreira, P. Rossignol, N. Girerd, and F. Zannad*

2618

### GREAT DEBATE



**Great debate: Plasma triglycerides are an important causal factor and therapeutic target for atherosclerotic cardiovascular disease**

*J. Borén, C. Packard, B.G. Nordestgaard, and A.L. Catapano*

2643

### META-ANALYSIS

**Heart rate-lowering drugs and outcomes in hypertension and/or cardiovascular disease: a meta-analysis**

*E. Sanidas, M. Böhm, I. Oikonomopoulou, P. Dinopoulou, D. Papadopoulos, H. Michalopoulou, K. Tsioufis, G. Mancia, and C. Thomopoulos*

2657

### Editorial

**The double-edged sword of heart rate lowering in cardiovascular disease**

*F.H. Messerli, L. Hofstetter, and S. Bangalore*

2670

### CLINICAL RESEARCH



**Systolic blood pressure variability: risk of cardiovascular events, chronic kidney disease, dementia, and death**

*X. Cheng, C. Song, F. Ouyang, T. Ma, L. He, F. Fang, G. Zhang, J. Huang, and Y. Bai*

2673

### Editorial

**Mind the gaps: blood pressure variability and its impact on health**

*S. Brouwers*

2688

**ApoB-containing lipoproteins: count, type, size, and risk of coronary artery disease**

*J. Morze, G.E.M. Melloni, C. Wittenbecher, M. Ala-Korpela, A. Rynkiewicz, M. Guasch-Ferré, C.T. Ruff, F.B. Hu, M.S. Sabatine, and N.A. Marston*

2691

### Editorial

**ApoB and Lp(a): core measures to assess cardiovascular risk**

*A.D. Sniderman, M.J. Pencina, and G. Thanassoulis*

2702

## DISCUSSION FORUM

- Oral health benefits and safety of xylitol and potential cardiovascular risk: questioning the validity of the model of Witkowski *et al.***  
*G.C. Valentine, E. Söderling, and P. Milgrom* 2705
- Xylitol and cardiovascular risks**  
*M. Witkowski and S.L. Hazen* 2707
- Mediterranean diet, neutrophil count, and atherosclerosis**  
*C. Saleh, K. Hovhannisyan, and H. Budincevic* 2709
- Discussion on Mediterranean diet, neutrophil count, and atherosclerosis**  
*J. Lopez-Miranda* 2710

## CARDIOVASCULAR FLASHLIGHTS

- Detection of large areas of thin-cap fibroatheroma in a recurrent STEMI patient using a novel artificial intelligence algorithm: moving from 2D to 3D**  
*T.J. Luttkholt, J. Thannhauser, and N. van Royen* 2712

## WEEKLY JOURNAL SCAN

- Weekly Journal Scan: a large observational study unravels the wide-ranging effects of glucagon-like peptide-1 receptor agonists**  
*D. Pedicino and M. Volpe* 2713



This paper is Editor's Choice and is available free online at <https://academic.oup.com/eurheartj>



Open Access Paper



For the podcast associated with this article, please visit <https://academic.oup.com/eurheartj/pages/Podcasts>

